February 10, 2023 – Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. PSA is one of the most widely used and ...